Daily steps are a predictor of, but perhaps not a modifiable risk factor for Parkinson’s Disease: findings from the UK Biobank - Acquah, Aidan; Creagh, Andrew; Hamy, Valentin; Shreves, Alaina; Zisou, Charilaos; Harper, Charlie; Van Duijvenboden, Stefan; Antoniades, Chrystalina; Bennett, Derrick; Clifton, David; Doherty, Aiden (medRxiv, 2024)
Importance Higher physical activity levels have been suggested as a potential modifiable risk factor for lowering the risk of incident Parkinson’s disease (PD). This study uses objective measures of physical activity to investigate the role of reverse causation in the observed association.Objective To investigate the association between accelerometer-derived daily step count and incident PD, and to assess the impact of reverse causation on this association.Design This prospective cohort study involved a follow-up period with a median duration of 7.9 years, with participants who wore wrist-worn accelerometers for up to 7 days.Setting The study was conducted within the UK Biobank, a large, population-based cohort.Participants The analysis included 94,696 participants aged 43-78 years (56% female) from the UK Biobank who provided valid accelerometer data and did not have prevalent PD.Exposure Daily step counts were derived using machine learning models to determine the median daily step count over the monitoring period.Main Outcomes and Measures The primary outcome was incident PD, identified through hospital admission and death records. Cox proportional hazards regression models estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association between daily step count and incident PD, with adjustments for various covariates and evaluation of reverse causation by splitting follow-up periods.Results During a median follow-up of 7.9 years (IQR: 7.4-8.4), 407 incident PD cases were identified. An inverse linear association was observed between daily step count and incident PD. Participants in the highest quintile of daily steps (>12,369 steps) had an HR of 0.41 (95% CI 0.31-0.54) compared to the lowest quintile (<6,276 steps; HR 1.00; 95% CI 0.84-1.19). A per 1,000 step increase was associated with an HR of 0.92 (95% CI 0.89-0.94). However, after excluding the first six years of follow-up, the association was not significant (HR 0.96, 95% CI 0.92-1.01).Conclusions and Relevance The observed association between higher daily step count and lower incident PD is likely influenced by reverse causation, suggesting changes in physical activity levels occur years before PD diagnosis. While step counts may serve as a predictor for PD, they may not represent a modifiable risk factor. Further research with extended follow-up periods is warranted to better understand this relationship and account for reverse causation.Question Is there an association between accelerometer-derived daily step count and the risk of incident Parkinson’s disease, considering the potential impact of reverse causation?Findings In this prospective cohort study of 94,696 UK Biobank participants, an inverse association was found between daily step count and incident Parkinson’s disease over a median follow-up of 7.9 years. However, this association was attenuated when excluding the first six years of follow-up.Meaning While daily step counts may be associated with incident Parkinson’s disease, these observations are likely influenced by reverse causation, indicating changes in daily behaviours years before diagnosis.Competing Interest StatementConflict of Interest Disclosures: AS, CZ, CH, SvD, CA and DB declare no competing interests. AA, AC and DC were supported by GSK during this research. VH is an employee at GSK. AD has received research grants from SwissRe and Novo Nordisk. AA, AC and AD have released the stepcount package software under an academic use licence that could result in commercial entities paying license fees for their use. The funders/sponsors had no role in the design of this study or the analysis and interpretation of the results. Although VH is an employee of GSK that funded this research, he did not influence the study's results.Funding StatementThis research has been conducted using the UK Biobank Resource under Application Number 59070. This research is supported by the EPSRC Centre for Doctoral Training in Health Data Science (EP/S02428X/1), and by GlaxoSmithKline as part of an iCase studentship (EP/V519741/1). AD and SvD are supported by the Wellcome Trust [223100/Z/21/Z]. AD and DB are supported by Novo Nordisk. AD, CH, and DB are supported by SwissRe. CZ and AD are supported by the Oxford BHF Centre of Research Excellence [RE/18/3/34214]. DC is supported by the Pandemic Sciences Institute at the University of Oxford; the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC); an NIHR Research Professorship; a Royal Academy of Engineering Research Chair; the Wellcome Trust funded VITAL project (grant 204904/Z/16/Z); the EPSRC (grant EP/W031744/1); and the InnoHK Hong Kong Centre for Cerebro-cardiovascular Engineering (COCHE). AS is supported by the National Institutes of Health's Intramural Research Program and by the National Institutes of Health's Oxford Cambridge Scholars Program. CA is supported by the National Institute for Health Research Oxford Biomedical Research Centre and has received research grant support from UCB Pharma.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study uses UK Biobank data, available at: https://www.ukbiobank.ac.uk/enable-your-research/apply-for-accessI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access